Deniz N. Gezer

Aachen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2026

Prospective systematic classification of causes of death in the course of multiple myeloma.

Prospective systematic classification of causes of death in the course of multiple myeloma.

Journal: Blood cancer journal

Published: July 02, 2025

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2024

A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

Journal: HemaSphere

Published: October 01, 2024

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Journal: HemaSphere

Published: June 01, 2024

Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma.

Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma.

Journal: European journal of haematology

Published: February 28, 2024

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Real-world analysis of teclistamab in 123 RRMM patients from Germany.

Journal: Leukemia

Published: November 10, 2023

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.

Journal: Frontiers in oncology

Published: August 14, 2023

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Journal: Annals of hematology

Published: October 22, 2022

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.

Journal: Annals of hematology

Published: June 24, 2022

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: June 11, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026